Regular ArticleThe von Hippel–Lindau Tumor Suppressor Gene
References (122)
- et al.
Mosaicism in von Hippel–Lindau disease: Lessons from kindreds with germline mutations identified in offspring with mosaic parents
Am. J. Hum. Genet.
(2000) - et al.
Comparative sequence analysis of the VHL tumor suppressor gene
Genomics
(2000) - et al.
Immunostaining of the von Hippel–Lindau gene product (pVHL) in normal and neoplastic human tissues
Hum. Pathol.
(1997) - et al.
Ran-mediated nuclear export of the von Hippel–Lindau tumor suppressor protein occurs independently of its assembly with cullin-2
J. Biol. Chem.
(2000) - et al.
Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway
Cell
(1996) Cell cycle: Cull and destroy
Curr. Biol.
(1996)- et al.
SKP1 connects cell cycle regulators to he ubiquitin proteolysis machinery through a novel motif, the F-box
Cell
(1996) - et al.
ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity
Mol. Cell
(1999) - et al.
Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of lκBα
Mol. Cell
(1999) - et al.
Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization
J. Biol. Chem.
(2000)
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein
J. Biol. Chem.
(2000)
The von Hippel–Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix
Mol. Cell
(1998)
Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC
Mol. Cell
(1999)
An important von Hippel–Lindau tumor suppressor domain mediates Sp1-binding and self-association
Biochem. Biophys. Res. Commun.
(1999)
Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes
Biochem. Biophys. Res. Commun.
(1999)
The von Hippel–Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
J. Biol. Chem.
(1997)
Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel–Lindau gene product in renal cancer
J. Biol. Chem.
(2000)
Drosophila von Hippel–Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity
Biochem. Biophys. Res. Commun.
(2000)
Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha
Am. J. Pathol.
(1998)
von Hippel–Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel–Lindau disease
Hum. Pathol.
(1997)
Mendelian Inheritance in Man.
(1992)
Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes)
Trans. Ophthalmol. Soc. UK
(1894)
Zur Frage der Angiomatosis Retinae und Ihrer Hirncomplikation
Acta Opthalmol.
(1927)
Ueber eine sehr seltene Erkrankung der Nethaut
Graefe Arch. Ophthalmol.
(1904)
von Hippel–Lindau disease
Medicine
(1997)
von Hippel–Lindau disease
Von-Hippel Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma
Nature
(1988)
Identification of the von Hippel–Lindau disease tumor suppressor gene
Science
(1993)
Improved detection of germline mutations in the von Hippel–Lindau disease tumor suppressor gene
Hum. Mutat.
(1998)
Somatic mosaicism in von Hippel–Lindau disease
Hum. Mutat.
(2000)
Genotype–phenotype correlations in von Hippel–Lindau disease
J. Intern. Med.
(1998)
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type 2
JAMA
(1995)
Isolated familial pheochromocytoma as a variant of von Hippel–Lindau disease
J. Clin. Endocrinol. Metab.
(1996)
Mutations in the RET proto-oncogene and the von Hippel–Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas
J. Med. Genet.
(1995)
Germline mutations in the vhl gene in patients presenting with phaeochromocytomas
Int. J. Cancer
(1998)
Molecular genetic diagnosis of von Hippel–Lindau disease in familial phaeochromocytoma
J. Med. Genet.
(1995)
Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas
Cancer Res.
(1998)
Somatic mutations of the von Hippel–Lindau tumor supressor gene in sporadic central nervous systems hemangioblastomas
Cancer Res.
(1994)
Molecular genetic analysis of the von Hippel–Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas
Am. J. Clin. Pathol.
(1997)
Mutation of the Von Hippel–Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system
J. Pathol.
(1996)
Germline and somatic mutations in von Hippel–Lindau disease gene and its significance in the development of kidney cancer
Contrib. Nephrol.
(1999)
Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas
Cancer Res.
(1994)
Somatic mutations of the von Hippel–Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma
Hum. Mol. Genet.
(1994)
Germ-line mutations in the von Hippel–Lindau tumor suppressor gene are similar to somatic von Hippel–Lindau abberations in sporadic renal cell carcinoma
Am. J. Hum. Genet.
(1994)
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel–Lindau disease patients
Am. J. Pathol.
(1996)
Detection of von Hippel–Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens
Modern Pathol.
(1996)
Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis
Genes Chromosomes Cancer
(1998)
Mutations of the VHL tumour suppressor gene in renal carcinoma
Nature Genet.
(1994)
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
Proc. Natl. Acad. Sci. USA
(1994)
Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases
J. Clin. Endocrinol. Metab.
(1996)
Cited by (189)
Downregulation of the Raf kinase inhibitory protein (RKIP) in clear cell renal cell carcinoma associates with poor prognosis
2020, Prognostic and Therapeutic Applications of RKIP in CancerDesign, synthesis, and biological evaluation of selective hCA IX inhibitors
2020, pH-Interfering Agents as Chemosensitizers in Cancer TherapyExtraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene
2018, Pathology Research and PracticeStructure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing
2018, European Journal of Medicinal ChemistryGRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism
2017, Cytokine and Growth Factor Reviews
- 1
To whom reprint requests should be addressed. Fax: (617)-632-4760. E-mail: [email protected].
Copyright © 2001 Academic Press. All rights reserved.